



LETTER TO THE EDITOR

Obesity-associated mortality risk: Chronic kidney disease in focus



Dear Editors,

Dhalwani N.N. et al. [1] reported relevant data concerning mortality risk in obese patients with or without diabetes: HR 0.65, 95%CI 0.62–0.73 and HR 0.95 95%CI 0.91–0.99 respectively and these values highlighted the protective role of obesity.

According to this point, the already known “Obesity Paradox” has been assessed in obese chronic kidney disease (CKD) patients [2,3]. Indeed, Fleischmann et al. [2] showed higher survival rates for CKD patients on hemodialysis (HD) with Body Mass Index (BMI) \geq 27.5 than for patients with a BMI from 20.0 to 27.5.

In addition, the Dialysis Outcome and Practice Pattern Study (DOPPS) [3] reported a lower relative risk of mortality for overweight and obese HD patients: RR 0.84 p 0.00 and RR 0.73 p 0.00 respectively than patients with a normal BMI of 23–24.9 kg/m².

Unfortunately, Dhalwani et al. did not report the prevalence of CKD in the baseline data of their study population, probably because this value was missing in the UK Biobank resource, but it would have been of note if the protective role of obesity in both diabetic and non-diabetic individuals was maintained regardless the CKD status.

Chooi YC et al. [4] reported in their review alarming data concerning the prevalence of overweight and obesity in nearly a third of the world population, with low and middle socio-demographic-index countries experiencing the highest increase in the last decades compared to developed ones where obesity rate reached already a plateau [5].

We aim to point out that a similar trend has also been observed for chronic kidney disease (CKD), concerning both disease rate and geography, thus remarking the link between obesity and CKD [6]. Furthermore, the observation that CKD risk extends to obese who are metabolically healthy, indicates that obesity may contribute to CKD independently of metabolic complications [7]. Unfortunately, nowadays we are missing of reliable markers for the early identification and prompt management of CKD in obese subjects. Considering the underlying mechanisms by which obesity may promote CKD, albuminuria seems to

be the more evident clinical manifestation of kidney derangement. Obesity-related mechanism involved in the onset and progression of CKD include both metabolic (hyperinsulinaemia, hyperglycemia and dyslipidemia) and hemodynamic factors (raised renal plasma flow, activated tissue renin-angiotensin-aldosterone system and hyperfiltration) [8,9].

Considering that the glomerular filtration rate (GFR) in obese individuals tends to increase due to the raised renal plasma flow and sodium reabsorption in the proximal tubule, GFR assessment is not a reliable measure to estimate renal function and to early diagnose mild to moderate CKD in obese patients [9]. In this setting, albuminuria might reveal in advance CKD in obesity [10].

Unfortunately, there is currently a gap in the obesity guidelines regarding the regular assessment of albuminuria [11,12], while both international [13] and national [14] diabetes mellitus guidelines have thoroughly indicated albuminuria as an independent marker of CKD progression and recommend its periodical quantification. Therefore, it could be the time to “enhance” the role of albuminuria as a biomarker for the obesity-related CKD onset and progression.

Acknowledgements

The authors disclose any conflict of interest and/or funding underlying the preparation of the manuscript.

References

- [1] Dhalwani NN, Zaccardi F, Davies MJ, Khunti K. Body mass index and mortality in people with and without diabetes: a UK Biobank study. *Nutr Metabol Cardiovasc Dis* 2018 Jul 29; S0939–4753(18):30232–41. <https://doi.org/10.1016/j.numecd.2018.07.007> [Epub ahead of print]. PMID: 30309720.
- [2] Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. *Kidney Int* 1999 Apr;55(4):1560–7. Erratum in: *Kidney Int* 2000 Feb; 57(2): 760. PMID: 10201023.
- [3] Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in ‘healthier’ as

- compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant* 2001 Dec;16(12):2386–94.
- [4] Chooi YC, Ding C, Magkos F. The epidemiology of obesity. *Metabolism* 2018 Sep 22;S0026–0495(18):30194–X. <https://doi.org/10.1016/j.metabol.2018.09.005> [Epub ahead of print].
- [5] Afshin A, Forouzanfar MH, Reitsma MB. Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med* 2017 Jul 6;377(1):13–27. <https://doi.org/10.1056/NEJMoa1614362>. Epub 2017 Jun 12.
- [6] Whaley-Connell A, Sowers JR. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. *Kidney Int* 2017 Aug;92(2):313–23. <https://doi.org/10.1016/j.kint.2016.12.034>. Epub 2017 Mar 22. PMID 28341271.
- [7] Vivante A, Golan E, Tzur D, Leiba A, Tirosh A, Skorecki K, et al. Body mass index in 1.2 million adolescents and risk for end-stage renal disease. *Arch Intern Med* 2012 Nov 26;172(21):1644–50.
- [8] Porter LE, Hollenberg NK. Obesity, salt intake, and renal perfusion in healthy humans. *Hypertension* 1998 Jul;32(1):144–8.
- [9] Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafer U. Glomerular hemodynamics in severe obesity. *Am J Physiol Renal Physiol* 2000 May;278(5):F817–22. PMID: 10807594.
- [10] Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. *J Am Soc Nephrol* 2001 Jun;12(6):1211–7. PMID: 11373344.
- 11 Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *J Am Coll Cardiol* 2014 Jul 1;63(25 Pt B):2985–3023. <https://doi.org/10.1016/j.jacc.2013.11>.
- 12 Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, et al. American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action. *Endocr Pract* 2014 Sep;20(9):956–76. <https://doi.org/10.4158/EP14279.CS>.
- [13] Sinclair A, Morley JE, Rodriguez-Mañas L. Diabetes mellitus in older people: position statement on behalf of the international association of gerontology and geriatrics (IAGG), the european diabetes working party for older people (EDWPOP), and the international task force of experts in diabetes. *J Am Med Dir Assoc* 2012 Jul;13(6):497–502. <https://doi.org/10.1016/j.jamda.2012.04.012>.
- [14] American Diabetes Association Classification and Diagnosis of Diabetes. Standards of medical care in diabetes-2018. *Diabetes Care* 2018 Jan;41(Suppl 1):S13–27. <https://doi.org/10.2337/dc18-S002>.

L. Spatola*

Renal and Hemodialysis Unit, Humanitas Clinical and Research Hospital, via Manzoni 56, CAP 20089, Rozzano, MI, Italy

E. Dozio

Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy
Laboratory of Molecular Pathology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy

*Corresponding author. Fax: +39 02 8224 2992.
E-mail address: Leonardo.spatola@yahoo.it (L. Spatola)

15 November 2018

Handling Editor: Francesco Cappuccio